Abstract
Clinical studies employing high-dose Ara-C combined with MX have shown this combination to be an effective treatment of refractory acute leukemia, comparing favorably with other regimens employing high-dose Ara-C [1–5]. Drugs have been used empirically with regard to their sequencing. Some investigations have focussed on optimizing drug sequencing for this kind of chemotherapy [6–9]. We sought to investigate the synergism of Ara-C and MX in an in vitro model using a human leukemic cell line and human CFU-GM as targets.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Willemze R, Zwaan FE, Colpin G, Keuning JJ (1982) High-dose cytosine arabinoside in the management of refractory acute leukemia. Scand J Haematol 29:141–146
Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983) High-dose cytosine arabinoside therapy for refractroy leukemia. Blood 62:361–369
Capizzi RL, Poole M, Cooper MR, Richards FII, Stuart JJ, Jackson DV Jr, White DR, Spurr CL, Hopkins JO, Muss HB, Rudnick SA, Wells R, Gabriel D, Ross D (1984) Treatment of poor risk acute leukemia with sequen¬tial high-dose Ara-C and asparaginase. Blood 63:694–700
Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP (1985) High-dose cytosine-ara-binoside therapy with and without anthracycline antibiotics for remission re-induction of acute nonlymphoblastic leukemia. J Clin Oncol 3:992–997
Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1987) High-dose cytosine arabinoside and mitoxantrone:a highly effective regimen in refractory acute myeloid leukemia. Blood 69:744–749
Burke PJ, Karp JE (1987) Long remissions in adults with leukemia treated with two courses of timed drugs. Proc Am Assoc Cancer Res Am Soc Clin Oncol 6:153
Colly LP, Van Bekkum DW, Hagenbeek A (1984) Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model ( BNML) for human acute myelocytic leukemia. Leuk Res 8:953
Fountzilas G, Ohnuma T, Okano T, Greenspan EM, Holland JF (1983) Schedule-dependent synergism of cytosine arabinoside (ARA-C) with mitoxantrone in human acute myelogenous leukemia cell line HL-60. Proc Am Assoc Cancer Res Am Soc Clin Oncol 2:179
Edelstein M, Vietti T, Valeriote F (1974) Schedule dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin. Cancer Res 34:293
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Krehmeier, C., Zühlsdorf, M., Büchner, T., Hiddemann, W. (1990). Synergistic Cytotoxicity of Cytosine Arabinoside and Mitoxantrone for K562 and CFU-GM. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-74643-7_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50984-4
Online ISBN: 978-3-642-74643-7
eBook Packages: Springer Book Archive